Abstract:BACKGROUND Hepatocellular carcinoma (HCC) is the third leading cause of death from malignant tumors worldwide. More than 50% of HCC cases occur in China. The prognosis remains poor and overall efficacy is still unsatisfactory. Chemotherapy resistance is the most important reason for the poor outcome. Much progress has been made in the study of chemotherapy resistance of HCC; however, the specific mechanisms of progression of HCC have still only been partially established. Therefore, the mechanism of chemotherapy resistance in HCC requires more research. AIM To investigate the effect of miR-34a expression on the growth inhibition of HepG2 cells by doxorubicin. METHODS A recombinant lentiviral vector containing miR-34a was constructed and transfected into HepG2 cells. The expression of miR-34a was detected by reverse transcription-polymerase chain reaction (commonly known as RT-PCR) before and after transfection. Cells were exposed to 2 μM doxorubicin or phosphate-buffered saline before and after transfection. Cell viability in each group was detected by MTT assay, and cell cycle and apoptosis were detected by flow cytometry. Changes in expression levels of phospho (p)-p53, sirtuin (SIRT) 1, cyclin D1, cyclin-dependent kinase (CDK) 4, CDK6, BCL-2, multidrug resistance protein (MDR) 1/P glycoprotein (P-gp), and AXL were detected by Western blotting. RESULTS Recombinant lentiviral vector LV-hsa-mir-34a was successfully constructed by restriction endonuclease digestion and sequencing. RT-PCR showed that expression of miR-34a in HepG2 cells was significantly upregulated after transfection (P < 0.01). MTT assay showed that growth of HepG2 cells was inhibited after upregulation of miR-34a, and viability was significantly decreased after combined treatment with doxorubicin (P < 0.01). Flow cytometry showed that the number of HepG2 cells in G1 phase increased, and G1 phase arrest was more obvious after intervention with doxorubicin (P < 0.01). The apoptosis rate of HepG2 cells was increased after upregulation of miR-34a, and became more obvious after intervention with doxorubicin (P < 0.01). Western blotting showed that upregulation of miR-34a combined with treatment with doxorubicin caused significant changes in the expression levels of p-p53, SIRT1, cyclin D1, CDK4, CDK6, BCL-2, MDR1/P-gp and AXL proteins (P < 0.01). CONCLUSION MiR-34a may enhance the inhibitory effect of doxorubicin by downregulating MDR1/P-gp and AXL, which may be related to p53 expression.

Microrna-760 Inhibits Doxorubicin Resistance In Hepatocellular Carcinoma Through Regulating Notch1/Hes1-Pten/Akt Signaling Pathway

MicroRNA-383 Inhibits Doxorubicin Resistance in Hepatocellular Carcinoma by Targeting Eukaryotic Translation Initiation Factor 5A2.

Mir-760 Mediates Chemoresistance Through Inhibition of Epithelial Mesenchymal Transition in Breast Cancer Cells.

MiR-34a Overexpression Enhances the Inhibitory Effect of Doxorubicin on HepG2 Cells

Inhibitory Effect of Mir-140-5p on Doxorubicin Resistance of Hepatocellular Carcinoma.

Genome-Wide Analysis Of Mirna Signature Differentially Expressed In Doxorubicin-Resistant And Parental Human Hepatocellular Carcinoma Cell Lines

miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling.

microRNA-874 suppresses tumor proliferation and metastasis in hepatocellular carcinoma by targeting the DOR/EGFR/ERK pathway

Mir-26B Enhances the Sensitivity of Hepatocellular Carcinoma to Doxorubicin Via USP9X-dependent Degradation of P53 and Regulation of Autophagy

Doxorubicin resistance in breast cancer xenografts and cell lines can be counterweighted by microRNA-140-3p, through PD-L1 suppression

MiR-770 Suppresses the Chemo-Resistance and Metastasis of Triple Negative Breast Cancer Via Direct Targeting of STMN1

Microrna-137 Inhibits Tumor Growth And Sensitizes Chemosensitivity To Paclitaxel And Cisplatin In Lung Cancer

MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells

MicroRNA-215 is Upregulated by Treatment with Adriamycin and Leads to the Chemoresistance of Hepatocellular Carcinoma Cells and Tissues.

MicroRNA-340 inhibits the proliferation and invasion of hepatocellular carcinoma cells by targeting JAK1

Mir-340 Reverses Cisplatin Resistance Of Hepatocellular Carcinoma Cell Lines By Targeting Nrf2-Dependent Antioxidant Pathway

MicroRNA-139 Inhibits Hepatocellular Carcinoma Cell Growth Through Down-Regulating Karyopherin Alpha 2

MicroRNA-26b Suppresses the NF-κB Signaling and Enhances the Chemosensitivity of Hepatocellular Carcinoma Cells by Targeting TAK1 and TAB3

Microrna-155-5p Promotes Hepatocellular Carcinoma Progression by Suppressing Pten Through the Pi3k/Akt Pathway

MiR-141 Activates Nrf2-Dependent Antioxidant Pathway via Down-Regulating the Expression of Keap1 Conferring the Resistance of Hepatocellular Carcinoma Cells to 5-Fluorouracil.

Mir-122 Enhances Sensitivity of Hepatocellular Carcinoma to Oxaliplatin Via Inhibiting MDR1 by Targeting Wnt/β-catenin Pathway.